Cargando…

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY

Detalles Bibliográficos
Autores principales:	Doorduijn, J., Issa, S., van der Holt, B., Minnema, M., Seute, T., Durian, M., Cull, G., van der Poel, M., Stevens, W., Zijlstra, J., Nijland, M., Mason, K., Beeker, A., Brandsma, D., van den Bent, M., Gonzalez, M., de Jong, D., Bromberg, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429217/ http://dx.doi.org/10.1097/01.HS9.0000847568.17124.58

Ejemplares similares

Extent of radiological response does not reflect survival in primary central nervous system lymphoma
por: van der Meulen, Matthijs, et al.
Publicado: (2021)

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial
por: Chamuleau, Martine E.D., et al.
Publicado: (2019)

The Veterinary Quarterly 2017 JCR impact factor increased from 1.176 to 1.492
por: van der Kolk, J.H., et al.
Publicado: (2019)

Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial
por: Doorduijn, Jeanette K., et al.
Publicado: (2020)

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
por: Rijneveld, Anita W., et al.
Publicado: (2022)

P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM’S MACROGLOBULINEMIA
por: Dimopoulos, M.-A., et al.
Publicado: (2022)

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study
por: Kersten, Marie José, et al.
Publicado: (2022)

B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
por: Musto, P., et al.
Publicado: (2023)

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
por: Stevens, Wendy B.C., et al.
Publicado: (2020)

Cases from the Practice of Dr. Hansen: Allg. Hom. Zeitung 23, ’90
Publicado: (1890)

Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
por: van der Meulen, Matthijs, et al.
Publicado: (2020)

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
por: Broers, Annoek E. C., et al.
Publicado: (2022)

S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL
por: Van Dijck, Ruben, et al.
Publicado: (2023)

B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS
por: van de Donk, N., et al.
Publicado: (2023)

Biomarkers in NHL
por: Malek, Sami N.
Publicado: (2011)

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
por: Kersten, Marie José, et al.
Publicado: (2020)

TRIM-NHL protein, NHL-2, modulates cell fate choices in the C. elegans germ line
por: Brenner, John L., et al.
Publicado: (2022)

The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed
por: Bakunina, Katerina, et al.
Publicado: (2021)

P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
por: Kersting, Sabina, et al.
Publicado: (2023)

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
por: Minnema, Monique C., et al.
Publicado: (2019)

An Unnoticed Symptom of Ipecacuanha, Clinically Verified by Dr. Mossa: Allg. Hom. Zeitung, No. 3, 1889
Publicado: (1889)

Exploring Potential Germline-Associated Roles of the TRIM-NHL Protein NHL-2 Through RNAi Screening
por: Davis, Gregory M., et al.
Publicado: (2017)

P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, K., et al.
Publicado: (2022)

The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON‐107 study
por: de Greef, Georgine E., et al.
Publicado: (2018)

1176. Quality of Life of Previously Healthy Subjects following Cryptococcal Meningoencephalitis
por: Dean, Owen, et al.
Publicado: (2020)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
por: Oliva, Stefania, et al.
Publicado: (2021)

MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma
por: van der Meulen, Matthijs, et al.
Publicado: (2021)

The TRIM-NHL protein NHL-2 is a co-factor in the nuclear and somatic RNAi pathways in C. elegans
por: Davis, Gregory M, et al.
Publicado: (2018)

The Role of Rituximab in Primary Central Nervous System Lymphoma
por: Bromberg, Jacoline E. C., et al.
Publicado: (2020)

Immunomodulatory Activity of Lactococcus lactis GCWB1176 in Cyclophosphamide-Induced Immunosuppression Model
por: Jin, Sun Woo, et al.
Publicado: (2020)

P1361: TREATMENT OF SEVERE STEROID-REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE-BLIND MULTI-CENTER HOVON-113 TRIAL
por: Oosten, L., et al.
Publicado: (2022)

Statistics of Small-Pox: Remarks on a Report of Dr. L. J. Keller, in the “Allg. Wiener Med. Zeitung”
por: Gradle, H.
Publicado: (1874)

Ocular findings in Noonan syndrome: a retrospective cohort study of 105 patients
por: van Trier, Dorothée C., et al.
Publicado: (2018)

The microwave cooling system in R1, Run 1176, 12.3.1981, Run 1196, 14.5.1981
por: Peschardt, E, et al.
Publicado: (1981)

Flow cytometry shows added value in diagnosing lymphoma in brain biopsies
por: van der Meulen, Matthijs, et al.
Publicado: (2018)

Stem cell hunt in NHL
por: Merkel, Olaf, et al.
Publicado: (2015)

NHL - Extranodal T-cell lymphoma
por: Devi, Seema, et al.
Publicado: (2015)

Acute painful lumbosacral paresthesia after intrathecal rituximab
por: Bromberg, J. E. C., et al.
Publicado: (2011)

P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, K., et al.
Publicado: (2023)

Prospective validation of the prognostic relevance of CD34(+)CD38(–) AML stem cell frequency in the HOVON-SAKK132 trial
por: Ngai, Lok Lam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sh62qlpc2489v8qlufvqdgiev9